Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEMA Fentanyl Long-term Extension for Breakthrough Cancer Pain
NCT00696137Phase 3Completed
- Sponsor
- BioDelivery Sciences International
- Start
- Jun 2008
- Primary completion
- Jul 2009
- Modality
- Orthosteric Ligands
01
Overview
Phase 3, open-label, single-arm trial of fentanyl in breakthrough cancer pain (BTcP), sponsored by BioDelivery Sciences International. Primary endpoint: Number of Deaths at 3 years. Started Jun 2008; status: completed.
02
Drugs
fentanyl
03
Conditions
breakthrough cancer pain (BTcP)
Beyond the preview
Go deeper on NCT00696137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00696137.